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Cross-talk between different cell types plays central roles both in cardiac homeostasis and in adaptive responses of the heart to stress.
Cardiomyocytes (CMs) send biological messages to the other cell types present in the heart including endothelial cells (ECs) and
fibroblasts. In turn, CMs receive messages from these cells. Recent evidence has now established that exosomes, nanosized secreted
extracellular vesicles, are crucial mediators of such messages. CMs, ECs, cardiac fibroblasts, and cardiac progenitor cells (CPCs)
release exosomes carrying nonrandomsubsets of proteins, lipids, andnucleic acids present in their cells of origin. Exosomes secreted
fromCMs are internalized by fibroblasts and regulate gene expression in these cells as well as in ECs. CPC-derived exosomes protect
CMs against apoptosis while also stimulating angiogenesis. They are rich in cardioprotective and proangiogenic microRNAs such
as miR-146, miR-210, and miR-132. When injected into infracted hearts in vivo, CPC-derived exosomes reduce infarct size and
improve cardiac function. Thus, exosomes are emerging both as key mediators of intercellular communication in the heart and as
therapeutic candidates for heart disease.
1. Introduction
While cardiomyocytes (CMs) make up a large part of the
volume of the heart, fibroblasts are the most abundant cell
type that accounts for ∼90% of the nonmyocyte cells present
within the heart [1]. Endothelial cells (ECs) and vascular
smooth muscle cells (VSMCs) are the other major cell
types present in the heart. Moreover, accumulating evidences
suggest that the adult mammalian heart may harbor a pool
of resident stem and cardiac progenitor cells (CPCs) that
participate in cardiac responses to injury and possibly in
physiological CMs turnover during aging [2, 3]. Cellular cross
talk plays a central role both in cardiac homeostasis and
in adaptive responses of the heart to stress. Chronic adap-
tive responses to stress, referred to as cardiac remodeling,
include interstitial fibrosis, CMs hypertrophy, and changes in
contractility and blood vessel density. Cells interact through
direct contact as well as through secreted molecules, such as
growth factors and cytokines, which bind to surface receptors
of target cells and activate intracellular molecular signaling
pathways downstream of these receptors. Aside from these
well-established modalities of intercellular communication,
emerging mechanisms include secreted extracellular vesicles
(EVs) and circulating RNA. Secreted EVs carry payloads of
proteins, lipids, and nucleic acids through interstitial fluid
and circulating blood. They can be taken up by a variety
of neighboring cells, as well as by cells at a distance [4, 5].
Growing evidence suggests that EVsmay not only play a cen-
tral role in the exchange of biological information between
cells but may also be clinically useful both as biomarkers
of cardiovascular diseases and as therapeutic candidates for
these diseases [6, 7].This review summarizes recent advances
in our knowledge of the biological role of EVs, with a focus on
exosomes (see below), in intercellular communication within
the heart. The therapeutic potential of EV-based approaches
in patients with heart disease will be briefly discussed.
2. Classes of EVs and Their Functional Roles
EVs can be categorized based on their mechanisms of
biogenesis and secretion. The major classes of EVs include
exosomes, microvesicles, and apoptotic bodies. Exosomes
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Figure 1: Biogenesis of exosomes. Exosomes are formed in the
late endosomal compartment. They contain proteins from coated
pits/lipid rafts in the cellular membrane, proteins directly sorted
to the MVBs from RER and GC, mRNA, microRNA, and DNA.
Exosomes are generated by inward budding of the limiting mem-
brane of MVB, thus preserving the same orientation and folding
of membrane-bound proteins on the exosomal membrane as those
on the plasma membrane. The MVBs containing the exosomes
either fuse with the plasma membrane to release exosomes or
are sent to lysosomes for degradation (GC, Golgi complex; MVB,
multivesicular body; and RER, rough endoplasmic reticulum).
are 40 to 150 nm diameter lipid vesicles that originate from
the endolysosomal pathway and are assembled into mul-
tivesicular bodies (MVBs) that either traffic to the lyso-
some or fuse with the plasma membrane and release their
contents of exosomes into the extracellular space [8, 9]
(Figure 1).Themechanism that directs exosomes to lysosome
versus extracellular space is poorly understood. Exosomes
released from the producing cell can bind to the plasma
membrane of the acceptor cell and be internalized through
either endocytosis or micropinocytosis [10]. In contrast to
exosomes, microvesicles typically range from 200 to 1000 nm
in diameter and arise by direct budding from the plasma
membrane [11]. Finally, apoptotic bodies range from 50 to
2000 nm in diameter and are generated through blebbing of
the surface of apoptotic cells [12].
Originally described as the mechanism by which reticu-
locytes discard superfluous receptors and protein complexes
as they mature to erythrocytes [13], exosomes are now recog-
nized as importantmediators of intercellular communication
in many organs including the heart [14–16]. In cancer, for
instance, exosomes can pass on malignancy from cell to
cell and shape the environment by stimulating blood vessel
formation while concomitantly inhibiting immune responses
to the tumor [17–19]. Similar roles for exosomes have been
proposed in viral infections [20, 21], as exosomes can shuttle
viral particles from cell to cell.
Exosomes carry proteins, lipids, and nucleic acids includ-
ing mRNA, DNA, and noncoding RNAs such as microRNAs
(miRNAs) and long noncoding RNAs (lnRNAs) [22–24]. By
targeting multiple transcripts in a coordinated manner, non-
coding RNAs regulate many cell processes. As an example,
miR-590 and miR-199a have been shown to reprogram adult
CMs to proliferate [25]. Of note, it has been demonstrated
that mRNAs contained in exosomes can be translated in
acceptor cells and that miRNAs traveling with exosomes can
inhibit gene expression and regulate biological functions in
these cells [26, 27].These findings indicate that exosomes can
function as vehicles for the exchange of genetic information
between cells [28].
It should be emphasized that the protein and RNA con-
tents of exosomes are nonrandom subsets of the protein and
RNA contents of their cells of origin [29]. The mechanisms
that regulate the biogenesis of exosomes and incorporation
of proteins and RNA into them are incompletely under-
stood.The endosomal sorting complex required for transport
(ESCRT) plays an important role in this regard. As an exam-
ple, RNA interference screens targeting 23 components of the
ESCRT machinery and associated proteins in MHC class II-
(MHC II-) expressing HeLa-CIITA cells showed that silenc-
ing of HRS, STAM1, or TSG101 reduced the secretion of EV-
associatedCD63 andMHCII but each gene altered differently
the size and/or protein composition of secreted EVs [30]. By
contrast, depletion of VPS4B augmented this secretion but
did not alter the features of EVs. Silencing of ALIX increased
MHC II exosomal secretion, as a result of an overall increase
in intracellular MHC II protein and mRNA levels. These
results revealed a role for selected ESCRT components and
accessory proteins in exosome secretion and composition.
The online compendium ExoCarta [31] provides an
updated list of the biomolecules that have been found in
exosomes. Exosome secretion by various cell types present in
the heart including CMs, ECs, fibroblasts, and CPCs has been
demonstrated. However, the role of these EVs in cellular cross
talk and cardiac homeostasis remains to be fully elucidated.
3. Exosomes Released from CMs Regulate
Cardiac Fibroblast and EC Functions
In 2007, Gupta and Knowlton [32] reported, for the first
time, that adult CMs release exosomes. Using differential
centrifugation and ultracentrifugation techniques, they were
able to isolate EVs, which were then categorized as exosomes,
from primary cultures of adult rat CMs. EVs were secreted by
CMs under baseline conditions, but brief hypoxia increased
their release. They contained heat shock protein 60 (Hsp60)
which, unlike Hsp70 and Hsp90, had not been previously
described in EVs from other cell types. It has been sug-
gested that extracellular Hsp60, when not in exosomes, may
trigger apoptosis in CMs via activation of Toll-like receptor
(TLR)4 [33]. The population of EVs secreted by CMs was
not homogeneous, ranging in diameter from 40 to 300 nm.
The exosomal marker flotillin-1 was detectable in 80% of
EVs. Proteomics analyses revealed that the protein content
of exosomes released from primary adult CMs included
cytosolic, sarcomeric, and mitochondrial proteins, differing
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significantly from other types of exosomes described in
the literature. These proteins included myomesin, myosin-
binding protein C, VCP (also known as p97 AAA-ATPase,
Cdc48, and transitional endoplasmic reticulum ATPase),
tropomyosin, and 𝛼-crystallin [33]. Ethanol, at concentra-
tions seen with the consumption of alcoholic beverages,
increased the release of exosomes fromCMs. Ethanol-treated
cells showed enhanced Cell-Rox red staining, consistent with
a mechanistic role of reactive oxygen species (ROS) in the
release of exosomes from CMs. Hypoxia/reoxygenation also
modified the protein content of exosomes released by CMs.
The interplay of CMs and cardiac fibroblasts plays
important roles in adaptive responses of the heart to
increased workload as a result of myocardial infarction (MI),
hypertension, or heart valve disease [34]. These responses
include hypertrophy, changes in contractility, and interstitial
fibrosis. This cellular interplay may result in CMs growth
or possibly proliferation, as well as changes in fibroblast
function that affect extracellular matrix. Waldenstro¨m et
al. [35] isolated EVs from media of cultured HL-1 cells,
an immortalized atrial myxoma cell line, by differential
centrifugation including preparative ultracentrifugation.
Isolated EVs were surrounded by a bilayered membrane
and flow cytometry revealed presence of both caveolin-3
and flotillin-1. Out of 1520 detected 2 mRNA, 423 could
be directly connected in a biological network. Moreover,
exosomal DNA transfer into fibroblasts was demonstrated.
Exosomes stained for DNA were seen in the fibroblasts
cytosol and even in the nuclei. Changes in gene expression
were detected in NIH-3T3 fibroblasts transfected by CM-
derived EVs. Among 333 gene expression changes, there
were 175 upregulations and 158 downregulations compared
with controls. These findings demonstrate that exosomes can
transfer genetic information from CMs to fibroblasts and
affect their transcript profiles. Clearly, these data in NIH-3T3
fibroblasts cultured in the presence of exosomes released by
HL-1 cells cannot be directly translated to adult CM-derived
exosomes and cardiac fibroblasts.
Another study by the same group analyzed mRNA pro-
files of exosomes released from HL-1 cells, under baseline
and stimulated conditions [36].The presence of transforming
growth factor- (TGF-) 𝛽2 or platelet-derived growth factor-
(PDGF-) BB in cell culture media altered the transcript
profiles of the exosomes. Common transcripts (217) were
found in all 3 groups. The number of transcripts detected in
the TGF-𝛽2-treated group and the PDGF-BB-treated group
was 562 and 300, respectively, as compared to 505 in the
control group.
Yu et al. [37] reported that prolonged hypoxia increased
levels of tumor necrosis factor- (TNF-) 𝛼 in exosomes
secreted by cultured neonatal CMs. They provided evi-
dence suggesting that, under hypoxia, hypoxia inducible
factor- (HIF-) 1𝛼 initiates expression of TNF-𝛼, mediated
by exosomes in CMs. Zhang et al. [38] showed that Hsp20
(HspB6), a small heat shock protein that is increased in blood
from cardiomyopathic hamsters, was secreted by cultured
CMs through exosomes and promoted angiogenesis. These
findings show that external stimuli can modify the molecular
content of exosomes secreted by CMs.
Recent evidence suggests CMsmay interplay with cardiac
ECs through exosomes. Wang et al. [39] reported that
exosomes secreted by CMs from adult Goto-Kakizaki rats, a
commonly used animal model of type 2 diabetes, inhibited
proliferation, migration, and tube-like formation in cocul-
turedmouse cardiac ECs, whereas exosomes secreted byCMs
from control Wistar rats induced the opposite effects. Exo-
somes from CMs from Goto-Kakizaki rats contained higher
levels of miR-320 but lower levels of miR-126, compared
to those from control rats, and these differences explained
most of the observed effects on cardiac ECs. Indeed, miR-
320 transfer into cardiac ECs using CMexosomes fromGoto-
Kakizaki rats downregulated target genes of miR-320, such as
insulin-like growth factor- (IGF-) 1, Hsp20, and Ets2. Recip-
rocally, knocking down of miR-320 abolished the antiangio-
genic effects of the exosomes. These data suggest exosome-
mediated miR-320 transfer from CMs into cardiac ECs may
inhibit angiogenesis.Thismechanism could participate in the
development of diabetic coronary microvascular disease.
4. Exosomes Released from ECs Regulate
VSMC, CPC, EC, and B Cell Functions
In the heart, ECs and CMs interact to match oxygen and
nutrient demand and supply. Acting in concert with endothe-
lial progenitor cells (EPCs) and stromal cells, ECs participate
in the maintenance of vascular integrity. It has been shown
that ECs release EVs including exosomes and that TNF-
𝛼 enhances intercellular adhesion protein-1 (ICAM-1) and
mRNA expression in these exosomes [40]. This observation
suggests that cellular stress may affect the protein and RNA
profiles of exosomes secreted by ECs, which implies a role
for exosomes in the propagation of stress between vascular
cells, and that analysis of the protein and RNA profiles of
EC-derived exosomes may provide information regarding
vascular stress. Another study by van Balkom et al. [41]
showed that EC-derived exosomes stimulate migration and
angiogenesis in target ECs in a miR-214-dependent man-
ner. Moreover, Hergenreider et al. [42] described an EV-
mediated, atheroprotective communication between ECs and
VSMCs involving miRNA transfer.
Ong et al. [43] recently showed that exosomes released
by cardiac ECs are actively internalized by CPCs in vitro.
ECs transfected with the HIF-1 gene secreted exosomes
enriched for miR-210 and miR-126. CPCs cultured in the
presence of exosomes from HIF-1-transfected ECs activated
prosurvival kinases and exhibited a glycolytic switch. In a
NOD/SCID mouse model of MI, CPC transplantation and
intramyocardial injection of nonviral microcircle plasmid
carrying the HIF-1 gene induced synergistic beneficial effects
that were mediated by miR-210 and miR-126. These findings
are consistent with the notion that EC-derived exosomes can
exert functional effects on CPCs.
Recently, Halkein et al. [44] reported that 16-kDa N-
terminal prolactin fragment, cleaved from the full-length
nursing hormone prolactin by cathepsin D, not only induced
the expression of miR-146a in ECs, leading to inhibition of
angiogenesis, but also enhanced the release of miR-146a-
enriched exosomes from ECs. These EC-derived exosomes
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could be taken up by CMs, resulting in increased miR-146a
levels and reduced expression of Erbb4, Notch1, and Irak1
(targets ofmiR-146a) inCMs, resulting in impairedmetabolic
activity and contractile function. These findings confirm a
miRNA-based intercellular communication system between
ECs and CMs through exosomes, while suggesting a role for
exosomes in peripartum cardiomyopathy.
Finally, Song et al. [45] reported that exosomes released
from murine cardiac ECs carried integrin 𝛼v𝛽6 that
converted the latent TGF-𝛽 expressed by B cells upon
lipopolysaccharide (LPS) stimulation to the active form,
TGF-𝛽. Thus, B cells released TGF-𝛽 in response to reexpo-
sure to cardiac EC-derived exosomes in the culture, inducing
less proliferation of effector T cells. These findings suggest
that EC-derived exosomesmay favor the generation of B cells
with immune suppressor functions.
5. Exosomes Released from Cardiac
Fibroblasts Regulate CM Functions
Cardiac fibroblasts regulate myocardial function via soluble
mediators in a paracrine manner [46, 47]. A key regulator of
cellular interactions between fibroblasts and CMs is TGF-𝛽
[48]. Bang et al. [49] recently showed that exosomes derived
from cardiac fibroblasts contained relatively high levels of
many miRNA passenger strands (“star” miRNAs) that nor-
mally undergo intracellular degradation, such as miR-21-3p
(miR-21*).They also showed that miR-21* is a potent stimula-
tor of CM hypertrophy through regulation of its target genes
sorbin and SH3 domain-containing protein 2 (SORBS2) as
well as PDZ and LIMdomain 5 (PDLIM5). Silencing SORBS2
or PDLIM5 in CMs induced hypertrophy, whereas phar-
macological blockade of miR-21* attenuated pathology in a
mousemodel of angiotensin-II-induced cardiac hypertrophy.
These findings suggest a role for exosomes released from
cardiac fibroblasts in the development of CMs hypertrophy.
6. Exosomes Released from Mesenchymal Stem
Cells (MSCs) and Bone Marrow CD34+ Cells
Regulate CM and EC Functions
Timmers et al. [50] reported that MSC conditioned medium
administered intravenously just before myocardial reperfu-
sion after ischemia reduced infarct size in pigs andmice. Exo-
somes from embryonic MSCs injected systemically before
reperfusion after coronary ligation similarly reduced infarct
size in mice [51]. Using a gene therapy approach, exosomes
secreted from GATA-4 overexpressing MSCs served as a
reservoir of antiapoptotic miRNAs for cardioprotection [52].
Bone marrow CD34+ stem cells exhibit angiogenic
paracrine activities. Sahoo et al. [53] identified exosomes
as the active component of these activities. CD34+ stem
cell-derived exosomes injected into ischemic mouse hearts
were selectively internalized by ECs and CMs but not by
fibroblasts. These exosomes improved cardiac function and
capillary density while reducing fibrosis in vivo. To sum
up, growing evidence suggests that exosomes derived from
various stem cell types such as MSCs and bone marrow
CD34+ cells may possess cardioprotective and proangiogenic
activities.
7. Exosomes Released from CPCs Are
Cardioprotective and Proangiogenic and
Improve Cardiac Function
Recently, Sahoo and Losordo [16] provided ultrastructural
evidence of exosome-like vesicles packed in MVBs of a CPC,
characterized by a large nucleus and a thin cytoplasm, in
a healthy mouse heart, as well as in the cytoplasm of CMs
from the left ventricle of a healthy human and from a patient
with ischemic heart disease. Using electron microscopy,
we likewise provided ultrastructural evidence of exosome-
like vesicles released by human cardiospheres in vitro (i.e.,
cellular aggregates formed by CPCs cultured in cardiosphere-
forming medium under low-adhesion conditions [54, 55])
and by cells in the mouse heart in vivo [56]. We also demon-
strated internalization of human CPC-derived exosomes by
HL-1 CMs in vitro (Figure 2). These exosomes were enriched
for several cardioprotective and proangiogenicmiRNAs, such
as miR-210, miR-132, and miR-146 compared with exosomes
secreted by normal human dermal fibroblasts (NHDFs) [57].
HL-1 cells cultured in the presence of CPC-derived exosomes
showed a time-dependent increase in the intracellular con-
centrations of miR-210 and miR-132 suggesting uptake of
CPC exosomes by these cells. On the other hand, Gray et
al. [58] reported that mouse CPC-derived exosomes were
internalized efficiently by cardiac fibroblasts but poorly by
CMs.These differences could be explained by species-specific
differences in the CPCs used as exosome donors as well
as in target CMs. Exosomes secreted by mouse CPCs in
response to hypoxia enhanced ECs tube formation while
reducing profibrotic gene expression in TGF-𝛽-stimulated
fibroblasts. Vrijsen et al. [59] showed that CPC-derived
exosomes stimulated the migration of ECs, in part due to
their matrix metalloproteinase (MMP) content.
Chen et al. [60] reported that mouse CPC-derived
exosomes attenuated CMs apoptosis in ischemic-reperfused
mouse hearts. Recent reports by Ibrahim et al. [61] and by
our own group [57] showed that exosomes from adult human
CPCs protected ischemic myocardium and regenerated the
heart after myocardial injury. Ibrahim et al. [61] employed
cardiosphere-derived cells (CDCs). CPCs obtained from
endomyocardial biopsies from the right ventricular aspect of
the interventricular septum from healthy hearts of deceased
tissue donors formed cardiospheres [54, 55], from which
CDCs were derived. By contrast, we obtained CPCs from
right atrial appendage specimens from patients who under-
went heart valve surgery [57]. Therefore, CDCs and CPCs
used in the two studies were related yet distinct populations
[57, 61]. EVs isolated from CPCs expressed the exosome
marker TSG101. Nanoparticle tracking analysis revealed that
they were not a pure exosomal population but also contained
a minor component of larger microvesicles (130–300 nm)
(Figure 3). CPC-derived exosomes inhibited apoptosis in
HL-1 cells induced by serum deprivation. Moreover they
stimulated tube formation of human umbilical vein ECs
(HUVECs). When injected into rat hearts at the time of
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Figure 2: CPC exosome uptake byHL-1 CMs. (A) Laser confocal fluorescence photomicrograph showingHL-1 cells cultured withDil-labeled
(blue) human CPC exosomes. (B) Corresponding bright photomicrograph. (b) Merge (high magnification).
MI, CPC-derived exosomes reduced CMs apoptosis and
scar size, increased viable mass and the number of newly
formed blood vessels, and improved cardiac function in
vivo. Exosomes from NHDFs, a therapeutically inert cell
type in this model, lacked these benefits. Human CDC-
derived exosomes similarly reduced CMs apoptosis under
stress conditions while promoting CMs proliferation and
angiogenesis in vitro [61]. When injected into the infarct
border zone of immunodeficient mice at the time of MI,
CDC exosomes improved global heart function, reduced scar
size, and increased viable mass and infarcted wall thickness
compared with NHDF exosomes. In a different model, CDC
exosomes injected at 21 days postinfarct, a time point at
which myocardial scar is well established [62], still reduced
CMs apoptosis and scar size while improving viable mass,
microvessels density, and cardiac function. These findings
using a model of late exosome administration after injury are
consistent with genuine cardiac regeneration.
8. miRNA Are Key Mediators of
Cardioprotective and Proangiogenic Effects
of CPC or CDC Exosomes
Exosomes secreted by different cell types differ in their
miRNA contents. By differential miRNA profiling, both us
and Ibrahim et al. [61] identified miR-146a as one of the most
highly enriched miRNA in CPC and CDC exosomes com-
pared to NHDF exosomes [57, 61]. Moreover, miR-146a
tissue levels were increased in hearts injected with CDC exo-
somes [61]. miR-146a exerted cardioprotective effects in
vitro. miR-146a knockout (KO) mice exhibited impaired
heart function, increased scar mass, decreased infarct wall
thickness, and worse postinfarct remodeling compared to
wild-type mice of the same strain. Injection of a miR-146a
mimic at the time of infarction “rescued” miR-146a KO
mice with respect to these changes. Moreover, miR-146a-
deficient exosomes, generated by transfecting CDCs with a
miR-146a hairpin inhibitor followed by exosome isolation,
showed impaired ability to protect CMs against oxidant stress
[61]. HumanCPC- or CDC-derived exosomes [57, 61], as well
as hypoxia-preconditioned mouse CPC exosomes [58], were
enriched for miR-210, a miRNA that has been implicated in
CM survival and stimulation of angiogenesis [57, 63]. CPC
exosomes also were enriched for miR-132, which similarly
participates in angiogenesis and vascular remodeling [57, 64].
Together, these results point to a key role for miRNA transfer
in the cardioprotective activities of CPC- or CDC-derived
exosomes. Of note, it has been demonstrated that miRNAs
can mediate long-lasting benefits and fundamental changes
in the microenvironment of injured tissue [65].
9. Exosomes Secreted by Immune Cells
Immune cells including dendritic cells, macrophages, and T
cells secrete immunologically active exosomes that influence
both physiological and pathological processes. The immuno-
logical activities of exosomes affect both innate and adaptive
immunity and include antigen presentation, T cell activation,
T cell polarization to regulatory T cells, immune suppression,
and anti-inflammatory effects [66, 67]. While the majority of
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Figure 3: (a) Nanoparticle tracking analysis of CPC conditioned medium (A) and isolated CPC exosomes (B) using the Nanosight system. A
minor peak at 287 nm seen in conditionedmedium is not seen in purified exosomes. (b)Western blot analysis of the exosomemarker TSG101
in exosomes isolated at the indicated time points of CPC cultures.
peripheral blood EVs are derived from platelets, mononu-
clear phagocytes, including macrophages, are the second
most abundant population [68]. RNAmolecules contained in
the macrophage-derived EVs are transported to target cells,
including ECs, fibroblasts, and monocytes, and they induce
the differentiation of naive monocytes into macrophages.
miR-223 transported by macrophage-derived EVs to target
cells is functionally active [68] and promotes ECs apoptosis
by advanced glycation end products by targeting the IGF-
1 receptor [69]. Body fluid exosomes can promote secre-
tion of inflammatory cytokines in monocytic cells via Toll-
like receptor signaling [70]. miRNA-containing EVs play
important roles in vascular inflammation and atherosclerosis,
which are discussed elsewhere [71].
In the setting of acute MI, the balance of macrophage
subtypes (M1 versus M2 polarized macrophages) migrating
into the infarcted region affects myocardial healing [72–74].
In another context, exosomes from cancer cells were shown
tomodulatemacrophage infiltration andM1/M2 polarization
[75].Therefore, exosomes released bymacrophagesmigrating
into the injured heart could affect infarct healing by pro-
moting monocyte differentiation into macrophages and by
influencing macrophage polarization.
10. Exosomes and Remote
Ischemic Preconditioning
Remote ischemic preconditioning induced by cycles of tran-
sient limb ischemia and reperfusion is a powerful car-
dioprotective strategy. Its underlying mechanisms are not
precisely known, however. Recently, it has been shown that
remote ischemic conditioning attenuates LV remodeling
and interstitial fibrosis in the boundary region of MI via
exosome-mediated intercellular communication [76]. This
effect was associated with increased expression of miR-
29a, a key regulator of tissue fibrosis, in exosomes and
the marginal area of MI. IGF-1 receptor, which signals in
the cardioprotective IGF-1 signaling pathway, was highly
expressed both in the exosomes and in remote noninfarcted
myocardium after remote ischemic conditioning. Another
study [77] showed that remote ischemic conditioning, unlike
ischemia/reperfusion, increased miR-144 levels in mouse
myocardium and miR-144 precursor in exosome pellets.
Systemic treatment with miR-144 increased P-Akt, P-GSK3𝛽,
and P-p44/42 MAPK, inducing early and delayed cardio-
protection with improved functional recovery and decreased
infarct size similar to that achieved by remote ischemic
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preconditioning. Conversely, systemic administration of a
specific antisense oligonucleotide reduced myocardial lev-
els of miR-144 and abrogated cardioprotection by remote
ischemic preconditioning.These results indicate a cardiopro-
tective role of miR-144 transported by exosomes.
11. Exosomes as Biomarkers of Heart Disease
As pointed out above, EVs including exosomes may be
clinically useful as biomarkers of cardiovascular diseases
[6, 7, 78–80]. A comprehensive discussion of this issue is
beyond the scope of this review. As an example, Matsumoto
et al. [81] reported a significant association of serum lev-
els of miR-192, particularly in exosomes, in patients who
experienced development of heart failure within 1 year after
MI, as compared to matched controls without subsequent
cardiovascular events after discharge. miR-192 is a p53-
responsive miRNA. Interestingly, the serum levels of two
other p53-responsive miRNAs, miR-194 and miR-34a, also
were coordinately increased with miR-192, suggesting that
these miRNAsmay function as circulating regulators of heart
failure development via the p53 pathway. miR-133 and miR-
328 are increased in plasma in patients afterMI and therefore
represent novel biomarkers of acute MI [82]. In this regard,
it should be emphasized that a majority of plasma and blood
miRNAs travel with EVs.
12. Potential Exosome-Based Therapeutic
Approaches for Heart Disease
Exosomes have been evaluated in a few clinical trials of
therapeutic vaccination for cancer [83, 84]. Exosomes used in
these trials were isolated from the conditioned media of den-
dritic cells that had been loaded with tumor antigen ex vivo.
They were administered in an autologous fashion to induce
antitumor immunity. In some patients, they elicited minor
inflammatory responses at the site of injection and low-grade
fever. However, repeated administration of exosomes was
safe. Collectively, initial clinical trials have demonstrated that
exosome therapy is feasible and safe in humans.
Proof-of-principle studies in animalmodels have demon-
strated benefits of CPC- or CDC-derived exosomes injected
intramyocardially [57, 58, 61], as mentioned above. Although
CPCs remain a good cell candidate, the most effective cell
type as a producer of cardioprotective exosomes remains
to be identified. Cell manipulations aiming at enhancing
beneficial properties of exosomes may include hypoxic and
stress preconditioning [58], genetic modification [84], and
epigenetic reprogramming of exosome-producing cells [85].
As cell-free therapeutic candidates, exosomes offer several
potential advantages over cell therapy. An important question
is whether allogeneic exosomes can be safely used in human.
Exosomes carry MHC I and/or II, depending on the expres-
sion pattern of these molecules in their cells of origin. While
allogeneic CDCs can be used in any recipient without adverse
safety effects in animal models, some recipients develop low-
level immune responses that may undermine the efficacy
of subsequent administrations of identical biomaterial. In a
recent study aiming at comparing the immunogenicity of
repeated doses of xenogeneic (human) and allogeneic CDCs
andCDC-derived EVs, subcutaneous injections of CDCs and
CDC-derived EVs were delivered in rats every 2 weeks for up
to 3 repeats [86]. As expected, repeated human (xenogeneic)
CDC injections resulted in rapid humoral and cell-mediated
immune responses, whereas delivery of humanCDC-derived
EVs did not induce any response after the first dose. Repeated
dosing led to progressively increased immunogenicity; how-
ever, the response was diminished compared to that observed
with human CDCs. Importantly, delivery of rat (allogeneic)
CDC-derived EVs did not elicit any significant immune
response even after repeated dosing. These results indicate
that allogeneic CDC-derived EV delivery without immuno-
suppression elicits no overt immunogenicity after repeated
dosing.
13. Conclusions
We have concisely discussed current evidence that exosomes
play central roles in exchanges of biological information
between cells, with a focus on the cross talk between the
major cell types present in the heart. We have summarized
recent data on cardioprotective and proangiogenic activities
of exosomes secreted by human adult CPCs andCDCs.These
exosomes are rich inmiRNAs endowedwith cardioprotective
and regenerative potential. Although we often think of stem
cell therapy acting to regenerate tissue through cell replica-
tion and then differentiation, growing evidence suggests that
adult stem cells may exert dramatic effects in the repair of
various tissues through secreted factors including exosomes
and EVs and not simply through differentiation [87]. Indeed,
up to 80% of the therapeutic activities of adult stem cells in
infarcted hearts have been shown to be through paracrine
mediated effects [88], giving rise to the novel notion of stem
cell therapy without the cells [87].
Attractive features of exosomes as noncellular therapeutic
candidates include the fact that they are cell permeant and
that their membrane protects their molecular cargoes from
degradation in the extracellular space. It has been shown that
benefits of CDC-derived exosomes injected into ischemic
hearts are comparable to those of their parent cells [61].
Recent data support the use of a repeated dose treatment
strategy with allogeneic CDC-derived EVs. This provides
great flexibility in the further development of this novel
cell-free regenerative therapy [86]. The lack of a robust
immune response may enable safe and effective repeated
dosing of CDC-derived EVs, a desirable feature in the
treatment of chronic diseases. Thus, EV-based therapies can
potentially circumvent some of the limitations associated
with cell transplantation including concerns over immune
sensitization with repeated dosing and use of allogeneic cells
[86, 89, 90]. Future studies need to further compare the
benefits of EV-based therapy with those associated with the
delivery of the corresponding EV-producing cells, as well as
confirming the safety of allogeneic EV-based therapy. Disease
conditions may influence the molecular content of EVs
and therefore their therapeutic potency. EVs derived from
healthy, young allogeneic donors may represent superior
therapeutic products in this regard. Moreover, cells may be
8 Stem Cells International
modified in vitro in order to produce EVs with enhanced
beneficial activities. Finally, exosomes may be extremely
useful as drug delivery systems [91–93]. For all these reasons,
exosomes may help streamline translational applications in
many fields of medicine.
Conflict of Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper.
Acknowledgments
This work was supported by the Swiss Heart Foundation, the
Swiss National Science Foundation, and the Cecilia-Augusta
Foundation, Lugano, Switzerland.
References
[1] P. Anversa, G. Olivetti, M. Melissari, and A. V. Loud, “Stere-
ological measurement of cellular and subcellular hypertrophy
and hyperplasia in the papillary muscle of adult rat,” Journal of
Molecular and Cellular Cardiology, vol. 12, no. 8, pp. 781–795,
1980.
[2] M. A. Laflamme and C. E. Murry, “Heart regeneration,”Nature,
vol. 473, no. 7347, pp. 326–335, 2011.
[3] L. Barile, E. Messina, A. Giacomello, and E. Marba´n, “Endoge-
nous cardiac stem cells,” Progress in Cardiovascular Diseases,
vol. 50, no. 1, pp. 31–48, 2007.
[4] C. The´ry, “Exosomes: secreted vesicles and intercellular com-
munications,” F1000 Biology Reports, vol. 3, article 15, 2011.
[5] P. J. Quesenberry, L. R. Goldberg, J. M. Aliotta et al., “Cellular
phenotype and extracellular vesicles: basic and clinical consid-
erations,” Stem Cells and Development, vol. 23, no. 13, pp. 1429–
1436, 2014.
[6] J. P. G. Sluijter, V. Verhage, J. C. Deddens, F. van den Akker, and
P.A.Doevendans, “Microvesicles and exosomes for intracardiac
communication,” Cardiovascular Research, vol. 102, no. 2, pp.
302–311, 2014.
[7] A. Khalyfa and D. Gozal, “Exosomal miRNAs as potential bio-
markers of cardiovascular risk in children,” Acta Veterinaria
Scandinavica, vol. 12, article 162, 2014.
[8] M. Simons and G. Raposo, “Exosomes—vesicular carriers for
intercellular communication,” Current Opinion in Cell Biology,
vol. 21, no. 4, pp. 575–581, 2009.
[9] K. Denzer, M. J. Kleijmeer, H. F. G. Heijnen, W. Stoorvogel,
and H. J. Geuze, “Exosome: from internal vesicle of the
multivesicular body to intercellular signaling device,” Journal of
Cell Science, vol. 113, no. 19, pp. 3365–3374, 2000.
[10] T. Tian, Y. Wang, H. Wang, Z. Zhu, and Z. Xiao, “Visualizing of
the cellular uptake and intracellular trafficking of exosomes by
live-cell microscopy,” Journal of Cellular Biochemistry, vol. 111,
no. 2, pp. 488–496, 2010.
[11] G. Camussi, M. C. Deregibus, S. Bruno, C. Grange, V. Fon-
sato, and C. Tetta, “Exosome/microvesicle-mediated epigenetic
reprogramming of cells,” American Journal of Cancer Research,
vol. 1, pp. 98–110, 2011.
[12] A. Zernecke, K. Bidzhekov, H. Noels et al., “Delivery of
microRNA-126 by apoptotic bodies induces CXCL12-depend-
ent vascular protection,” Science Signaling, vol. 2, no. 100, p. ra81,
2009.
[13] R. M. Johnstone, “Revisiting the road to the discovery of exo-
somes,” Blood Cells, Molecules, and Diseases, vol. 34, no. 3, pp.
214–219, 2005.
[14] S. Mathivanan, H. Ji, and R. J. Simpson, “Exosomes: extra-
cellular organelles important in intercellular communication,”
Journal of Proteomics, vol. 73, no. 10, pp. 1907–1920, 2010.
[15] A. Waldenstro¨m and G. Ronquist, “Role of exosomes in myo-
cardial remodeling,” Circulation Research, vol. 114, no. 2, pp.
315–324, 2014.
[16] S. Sahoo andD.W. Losordo, “Exosomes and cardiac repair after
myocardial infarction,” Circulation Research, vol. 114, no. 2, pp.
333–344, 2014.
[17] A. Clayton, “Cancer cells use exosomes as tools to manipulate
immunity and the microenvironment,” OncoImmunology, vol.
1, no. 1, pp. 78–80, 2012.
[18] L. M. Epple, S. G. Griffiths, A. M. Dechkovskaia et al., “Medul-
loblastoma exosome proteomics yield functional roles for extra-
cellular vesicles,” PLoS ONE, vol. 7, no. 7, Article ID e42064,
2012.
[19] D. D. Taylor and C. Gercel-Taylor, “Exosomes/microvesicles:
mediators of cancer-associated immunosuppressive microen-
vironments,” Seminars in Immunopathology, vol. 33, no. 5, pp.
441–454, 2011.
[20] A. M. Marleau, C.-S. Chen, J. A. Joyce, and R. H. Tullis, “Exo-
some removal as a therapeutic adjuvant in cancer,” Journal of
Translational Medicine, vol. 10, no. 1, article 134, 2012.
[21] D. G. Meckes Jr. and N. Raab-Traub, “Microvesicles and viral
infection,” Journal of Virology, vol. 85, no. 24, pp. 12844–12854,
2011.
[22] E. Hirsch, D. Hilfiker-Kleiner, J.-L. Balligand et al., “Interaction
of the heart and its close and distant neighbours: report of the
Meeting of the ESCWorking Groups Myocardial Function and
Cellular Biology,” Cardiovascular Research, vol. 99, no. 4, pp.
595–599, 2013.
[23] L. Lugini, S. Cecchetti, V. Huber et al., “Immune surveillance
properties of human NK cell-derived exosomes,”The Journal of
Immunology, vol. 189, no. 6, pp. 2833–2842, 2012.
[24] H. Zhu and G. C. Fan, “Extracellular/circulating microRNAs
and their potential role in cardiovascular disease,” American
Journal of Cardiovascular Disease, vol. 1, no. 2, pp. 138–149, 2011.
[25] A. Eulalio, M. Mano, M. D. Ferro et al., “Functional screening
identifies miRNAs inducing cardiac regeneration,” Nature, vol.
492, no. 7429, pp. 376–381, 2012.
[26] H. Valadi, K. Ekstro¨m, A. Bossios, M. Sjo¨strand, J. J. Lee,
and J. O. Lo¨tvall, “Exosome-mediated transfer of mRNAs and
microRNAs is a novel mechanism of genetic exchange between
cells,” Nature Cell Biology, vol. 9, no. 6, pp. 654–659, 2007.
[27] A. Montecalvo, A. T. Larregina, W. J. Shufesky et al., “Mech-
anism of transfer of functional microRNAs between mouse
dendritic cells via exosomes,” Blood, vol. 119, no. 3, pp. 756–766,
2012.
[28] M. Mittelbrunn and F. Sa´nchez-Madrid, “Intercellular commu-
nication: diverse structures for exchange of genetic informa-
tion,” Nature Reviews Molecular Cell Biology, vol. 13, no. 5, pp.
328–335, 2012.
[29] M. Colombo, G. Raposo, and C. The´ry, “Biogenesis, secretion,
and intercellular interactions of exosomes and other extracellu-
lar vesicles,” Annual Review of Cell and Developmental Biology,
vol. 30, no. 1, pp. 255–289, 2014.
[30] M. Colombo, C. Moita, G. van Niel et al., “Analysis of ESCRT
functions in exosome biogenesis, composition and secretion
Stem Cells International 9
highlights the heterogeneity of extracellular vesicles,” Journal of
Cell Science, vol. 126, part 24, pp. 5553–5565, 2013.
[31] R. J. Simpson, H. Kalra, and S. Mathivanan, “ExoCarta as a
resource for exosomal research,” Journal of Extracellular Vesi-
cles, vol. 1, Article ID 18374, 2012.
[32] S. Gupta and A. A. Knowlton, “HSP60 trafficking in adult
cardiac myocytes: role of the exosomal pathway,”The American
Journal of Physiology—Heart and Circulatory Physiology, vol.
292, no. 6, pp. H3052–H3056, 2007.
[33] Z. A. Malik, K. S. Kott, A. J. Poe et al., “Cardiac myocyte exo-
somes: Stability, HSP60, and proteomics,” American Journal of
Physiology—Heart and Circulatory Physiology, vol. 304, no. 7,
pp. H954–H965, 2013.
[34] R. Kakkar and R. T. Lee, “Intramyocardial fibroblast myocyte
communication,” Circulation Research, vol. 106, no. 1, pp. 47–57,
2010.
[35] A. Waldenstro¨m, N. Genneba¨ck, U. Hellman, and G. Ronquist,
“Cardiomyocyte microvesicles contain DNA/RNA and convey
biological messages to target cells,” PLoS ONE, vol. 7, no. 4,
Article ID e34653, 2012.
[36] N. Genneba¨ck, U. Hellman, L. Malm et al., “Growth factor
stimulation of cardiomyocytes induces changes in the transcrip-
tional contents of secreted exosomes,” Journal of Extracellular
Vesicles, vol. 2, 2013.
[37] X. Yu, L. Deng, D. Wang et al., “Mechanism of TNF-𝛼 auto-
crine effects in hypoxic cardiomyocytes: initiated by hypoxia
inducible factor 1𝛼, presented by exosomes,” Journal of Molec-
ular and Cellular Cardiology, vol. 53, no. 6, pp. 848–857, 2012.
[38] X. Zhang, X. Wang, H. Zhu et al., “Hsp20 functions as a
novel cardiokine in promoting angiogenesis via activation of
VEGFR2,” PLoS ONE, vol. 7, no. 3, Article ID e32765, 2012.
[39] X. Wang, W. Huang, G. Liu et al., “Cardiomyocytes mediate
anti-angiogenesis in type 2 diabetic rats through the exosomal
transfer of miR-320 into endothelial cells,” Journal of Molecular
and Cellular Cardiology, vol. 74, pp. 139–150, 2014.
[40] O. G. de Jong,M. C. Verhaar, Y. Chen et al., “Cellular stress con-
ditions are reflected in the protein and RNA content of endo-
thelial cell-derived exosomes,” Journal of Extracellular Vesicles,
vol. 1, 2012.
[41] B. W. M. van Balkom, O. G. de Jong, M. Smits et al., “Endothe-
lial cells require miR-214 to secrete exosomes that suppress
senescence and induce angiogenesis in human and mouse
endothelial cells.,” Blood, vol. 121, supplement 1, pp. 3997–4006,
2013.
[42] E. Hergenreider, S. Heydt, K. Tre´guer et al., “Atheroprotective
communication between endothelial cells and smooth muscle
cells through miRNAs,” Nature Cell Biology, vol. 14, no. 3, pp.
249–256, 2012.
[43] S. Ong, W. H. Lee, M. Huang et al., “Cross talk of combined
gene and cell therapy in ischemic heart disease: role of exosomal
microRNA transfer,” Circulation, vol. 130, pp. S60–S69, 2014.
[44] J. Halkein, S. P. Tabruyn, M. Ricke-Hoch et al., “MicroRNA-
146a is a therapeutic target and biomarker for peripartum
cardiomyopathy,” The Journal of Clinical Investigation, vol. 123,
no. 5, pp. 2143–2154, 2013.
[45] J. Song, X. Chen, M. Wang, Y. Xing, Z. Zheng, and S. Hu, “Car-
diac endothelial cell-derived exosomes induce specific regu-
latory B cells,” Scientific Reports, vol. 4, article 7583, 2014.
[46] D.M. Pedrotty, R. Y. Klinger, R.D. Kirkton, andN. Bursac, “Car-
diac fibroblast paracrine factors alter impulse conduction and
ion channel expression of neonatal rat cardiomyocytes,” Car-
diovascular Research, vol. 83, no. 4, pp. 688–697, 2009.
[47] K. Nakazato, W. Naganuma, K. Ogawa et al., “Attenuation of
ischemic myocardial injury and dysfunction by cardiac fibro-
blast-derived factor(s),” Fukushima Journal of Medical Science,
vol. 56, no. 1, pp. 1–16, 2010.
[48] J. E. Cartledge, C. Kane, P. Dias et al., “Functional crosstalk
between cardiac fibroblasts and adult cardiomyocytes by soluble
mediators,” Cardiovascular Research, vol. 105, no. 3, pp. 260–
270, 2015.
[49] C. Bang, S. Batkai, S. Dangwal et al., “Cardiac fibroblast-derived
microRNA passenger strand-enriched exosomes mediate car-
diomyocyte hypertrophy,” The Journal of Clinical Investigation,
vol. 124, no. 5, pp. 2136–2146, 2014.
[50] L. Timmers, S. K. Lim, F. Arslan et al., “Reduction ofmyocardial
infarct size by humanmesenchymal stem cell conditionedmed-
ium,” Stem Cell Research, vol. 1, no. 2, pp. 129–137, 2008.
[51] F. Arslan, R. C. Lai,M. B. Smeets et al., “Mesenchymal stem cell-
derived exosomes increase ATP levels, decrease oxidative stress
and activate PI3K/Akt pathway to enhance myocardial via-
bility and prevent adverse remodeling after myocardial ische-
mia/reperfusion injury,” Stem Cell Research, vol. 10, no. 3, pp.
301–312, 2013.
[52] B. Yu, M. Gong, Z. He et al., “Enhanced mesenchymal stem
cell survival induced by GATA-4 overexpression is partially
mediated by regulation of the miR-15 family,” International
Journal of Biochemistry and Cell Biology, vol. 45, no. 12, pp.
2724–2735, 2013.
[53] S. Sahoo, E. Klychko, T. Thorne et al., “Exosomes from human
CD34(+) stem cells mediate their proangiogenic paracrine
activity,” Circulation Research, vol. 109, no. 7, pp. 724–728, 2011.
[54] E. Messina, L. De Angelis, G. Frati et al., “Isolation and
expansion of adult cardiac stem cells from human and murine
heart,” Circulation Research, vol. 95, no. 9, pp. 911–921, 2004.
[55] L. Barile, M. Gherghiceanu, L. M. Popescu, T. Moccetti, and G.
Vassalli, “Human cardiospheres as a source of multipotent stem
and progenitor cells,” Stem Cells International, vol. 2013, Article
ID 916837, 10 pages, 2013.
[56] L. Barile, M. Gherghiceanu, L. M. Popescu, T. Moccetti, and
G. Vassalli, “Ultrastructural evidence of exosome secretion by
progenitor cells in adult mouse myocardium and adult human
cardiospheres,” Journal of Biomedicine and Biotechnology, vol.
2012, Article ID 354605, 10 pages, 2012.
[57] L. Barile, V. Lionetti, E. Cervio et al., “Extracellular vesicles from
human cardiac progenitor cells inhibit cardiomyocyte apoptosis
and improve cardiac function after myocardial infarction,”
Cardiovascular Research, vol. 103, no. 4, pp. 530–541, 2014.
[58] W. D. Gray, K. M. French, S. Ghosh-Choudhary et al., “Identifi-
cation of therapeutic covariant microRNA clusters in hypoxia-
treated cardiac progenitor cell exosomes using systems biology,”
Circulation Research, vol. 116, no. 2, pp. 255–263, 2015.
[59] K. R. Vrijsen, J. P. G. Sluijter, M. W. L. Schuchardt et al.,
“Cardiomyocyte progenitor cell-derived exosomes stimulate
migration of endothelial cells,” Journal of Cellular andMolecular
Medicine, vol. 14, no. 5, pp. 1064–1070, 2010.
[60] L. Chen, Y. Wang, Y. Pan et al., “Cardiac progenitor-derived
exosomes protect ischemic myocardium from acute ischemia/
reperfusion injury,” Biochemical and Biophysical Research Com-
munications, vol. 431, no. 3, pp. 566–571, 2013.
[61] A. G.-E. Ibrahim, K. Cheng, and E. Marba´n, “Exosomes as
critical agents of cardiac regeneration triggered by cell therapy,”
Stem Cell Reports, vol. 2, no. 5, pp. 606–619, 2014.
[62] J. I. Virag and C. E. Murry, “Myofibroblast and endothelial
cell proliferation during murine myocardial infarct repair,”
10 Stem Cells International
American Journal of Pathology, vol. 163, no. 6, pp. 2433–2440,
2003.
[63] S. Hu, M. Huang, Z. Li et al., “MicroRNA-210 as a novel therapy
for treatment of ischemic heart disease,” Circulation, vol. 122,
no. 11, pp. S124–S131, 2010.
[64] R. Katare, F. Riu, K. Mitchell et al., “Transplantation of human
pericyte progenitor cells improves the repair of infarcted heart
through activation of an angiogenic program involving micro-
RNA-132,” Circulation Research, vol. 109, no. 8, pp. 894–906,
2011.
[65] A. Osman, “MicroRNAs in health and disease—basic science
and clinical applications,” Clinical Laboratory, vol. 58, no. 5-6,
pp. 393–402, 2012.
[66] B. Zhang, Y. Yin, R. C. Lai, and S. K. Lim, “Immunotherapeutic
potential of extracellular vesicles,” Frontiers in Immunology, vol.
5, article 518, 2014.
[67] I. S. Okoye, S. M. Coomes, V. S. Pelly et al., “MicroRNA-con-
taining T-regulatory-cell-derived exosomes suppress patho-
genic T helper 1 cells,” Immunity, vol. 41, no. 1, pp. 89–103, 2014.
[68] N. Ismail, Y. Wang, D. Dakhlallah et al., “Macrophage micro-
vesicles induce macrophage differentiation and miR-223 trans-
fer,” Blood, vol. 121, no. 6, pp. 984–995, 2013.
[69] Y. Pan, H. Liang, H. Liu et al., “Platelet-secreted MicroRNA-
223 promotes endothelial cell apoptosis induced by advanced
glycation end products via targeting the insulin-like growth
factor 1 receptor,”The Journal of Immunology, vol. 192, no. 1, pp.
437–446, 2014.
[70] N. P. Bretz, J. Ridinger, A.-K. Rupp et al., “Body fluid exosomes
promote secretion of inflammatory cytokines in monocytic
cells via Toll-Like receptor signaling,” The Journal of Biological
Chemistry, vol. 288, no. 51, pp. 36691–36702, 2013.
[71] M. Hulsmans and P. Holvoet, “MicroRNA-containing micro-
vesicles regulating inflammation in association with atheroscle-
rotic disease,” Cardiovascular Research, vol. 100, no. 1, pp. 7–18,
2013.
[72] G. Courties, T. Heidt, M. Sebas et al., “In vivo silencing of the
transcription factor IRF5 reprograms the macrophage pheno-
type and improves infarct healing,” Journal of the American
College of Cardiology, vol. 63, no. 15, pp. 1556–1566, 2014.
[73] J. Weirather, U. Hofmann, N. Beyersdorf et al., “Foxp3+CD4+ T
cells improve healing aftermyocardial infarction bymodulating
monocyte/macrophage differentiation,” Circulation Research,
vol. 115, no. 1, pp. 55–67, 2014.
[74] T. Ben-Mordechai, D. Palevski, Y. Glucksam-Galnoy, I. Elron-
Gross, R. Margalit, and J. Leor, “Targeting macrophage subsets
for infarct repair,” Journal of Cardiovascular Pharmacology and
Therapeutics, vol. 20, no. 1, pp. 36–51, 2014.
[75] J.-Y. Jang, J.-K. Lee, Y.-K. Jeon, and C.-W. Kim, “Exosome
derived from epigallocatechin gallate treated breast cancer
cells suppresses tumor growth by inhibiting tumor-associated
macrophage infiltration andM2polarization,”BMCCancer, vol.
13, article 421, 2013.
[76] T. Yamaguchi, Y. Izumi, Y. Nakamura et al., “Repeated remote
ischemic conditioning attenuates left ventricular remodeling
via exosome-mediated intercellular communication on chronic
heart failure after myocardial infarction,” International Journal
of Cardiology, vol. 178, pp. 239–246, 2015.
[77] J. Li, S. Rohailla, N. Gelber et al., “MicroRNA-144 is a circulating
effector of remote ischemic preconditioning,” Basic Research in
Cardiology, vol. 109, no. 5, article 423, 2014.
[78] K. M. Danielson and S. Das, “Extracellular vesicles in heart
disease: excitement for the future ?”Exosomes andMicrovesicles,
vol. 2, no. 1, 2014.
[79] J. Cosme, P. P. Liu, and A. O. Gramolini, “The cardiovascular
exosome: current perspectives and potential,” Proteomics, vol.
13, no. 10-11, pp. 1654–1659, 2013.
[80] A. Agouni, R. Andriantsitohaina, and M. Martinez, “Micropar-
ticles as biomarkers of vascular dysfunction in metabolic
syndrome and its individual components,” Current Vascular
Pharmacology, vol. 12, no. 3, pp. 483–492, 2014.
[81] S. Matsumoto, Y. Sakata, S. Suna et al., “Circulating p53-
responsiveMicroRNAs are predictive indicators of heart failure
after acute myocardial infarction,”Circulation Research, vol. 113,
no. 3, pp. 322–326, 2013.
[82] R. Wang, N. Li, Y. Zhang, Y. Ran, and J. Pu, “Circulating micro
RNAs are promising novel biomarkers of acute myocardial
infarction,” InternalMedicine, vol. 50, no. 17, pp. 1789–1795, 2011.
[83] S. Viaud, C. The´ry, S. Ploix et al., “Dendritic cell-derived
exosomes for cancer immunotherapy: what’s next?” Cancer
Research, vol. 70, no. 4, pp. 1281–1285, 2010.
[84] G. G. Romagnoli, B. B. Zelante, P. A. Toniolo, I. K. Migliori,
and J. A. Barbuto, “Dendritic cell-derived exosomes may be a
tool for cancer immunotherapy by converting tumor cells into
immunogenic targets,” Frontiers in Immunology, vol. 5, article
692, 2015.
[85] S. Ailawadi, X. Wang, H. Gu, and G. C. Fan, “Pathologic func-
tion and therapeutic potential of exosomes in cardiovascular
disease,” Biochimica et Biophysica Acta (BBA)—Molecular Basis
of Disease, vol. 1852, no. 1, pp. 1–11, 2015.
[86] M. Mirotsou, A. Blusztanj, I. Tremmel et al., “Repeated doses of
cardiosphere-derived cell extracellular vesicles are hypo-immu-
nogenic,” in Proceedings of the Abstracts from the 4th Inter-
national Meeting of ISEV (ISEV ’15), Journal of Extracellu-
lar Vesicles, Abstract Number O-8C-4, Washington, DC,
USA, April 2015, http://www.journalofextracellularvesicles.net/
index.php/jev/article/view/27783.
[87] G. Maguire, “Stem cell therapy without the cells,” Communica-
tive and Integrative Biology, vol. 6, no. 6, Article ID e26631, 2013.
[88] I. Chimenti, R. R. Smith, T.-S. Li et al., “Relative roles of direct
regeneration versus paracrine effects of human cardiosphere-
derived cells transplanted into infarcted mice,” Circulation
Research, vol. 106, no. 5, pp. 971–980, 2010.
[89] K. M. Danielson and S. Das, “Extracellular vesicles in heart
disease: excitement for the future?” Exosomes Microvesicles, vol.
2, no. 1, 2014.
[90] D. M. Yellon and S. M. Davidson, “Exosomes: nanoparticles
involved in cardioprotection?”Circulation Research, vol. 114, no.
2, pp. 325–332, 2014.
[91] R. van der Meel, M. H. Fens, P. Vader, W. W. van Solinge, O.
Eniola-Adefeso, and R. M. Schiffelers, “Extracellular vesicles as
drug delivery systems: lessons from the liposome field,” Journal
of Controlled Release, vol. 195, pp. 72–85, 2014.
[92] A. Aryani andB.Denecke, “Exosomes as a nanodelivery system:
a key to the future of neuromedicine?”Molecular Neurobiology,
2014.
[93] M. J. Haney, N. L. Klyachko, Y. Zhao et al., “Exosomes as drug
delivery vehicles for Parkinson’s disease therapy,” Journal of
Controlled Release, vol. 207, pp. 18–30, 2015.
